Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines
Recommendations
As issued by the authors
Early glycaemic control using conventional glucose-lowering drugs (GLDs) prevents complications and preserves quality of life
Multifactorial management using effective GLDs and organ-protective drugs (e.g. statins and renin-angiotensin-aldosterone system inhibitors) improves outcomes
Individualised regimens with shared decision-making and treatment persistence maximise benefits and minimise harm
Metformin is a foundation therapy; no evidence supports first-line SGLT2i or GLP-1 RA monotherapy in low-risk individuals
Sulphonylureas are highly effective and affordable GLDs, important options (particularly in low-resource settings)
Initial combination therapy achieves early glycaemic control with increased durability vs stepwise GLD addition
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →